BLFS:NSD-BioLife Solutions, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 42.26

Change

0.00 (0.00)%

Market Cap

USD 1.71B

Volume

0.69M

Average Target Price

USD 55.83 (+32.12%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

N/A

USD104.07B 90.42 67.18
NVCR NovoCure Limited

N/A

USD22.55B 2,096.54 509.82
HOLX Hologic, Inc

N/A

USD16.04B 8.60 6.28
XRAY DENTSPLY SIRONA Inc

N/A

USD13.79B 80.28 26.52
MASI Masimo Corporation

N/A

USD13.20B 60.91 42.12
RGEN Repligen Corporation

N/A

USD10.83B 135.54 85.59
STAA STAAR Surgical Company

N/A

USD6.82B 658.28 359.22
ICUI ICU Medical, Inc

N/A

USD4.31B 46.93 19.43
ATRC AtriCure, Inc

N/A

USD3.40B N/A N/A
MMSI Merit Medical Systems, Inc

N/A

USD3.37B 803.20 33.15

ETFs Containing BLFS

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.94% 48% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.94% 48% F 46% F
Trailing 12 Months  
Capital Gain 160.06% 90% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 160.06% 90% A- 90% A-
Trailing 5 Years  
Capital Gain 2,507.03% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,507.03% 96% A 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 134.84% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.84% 94% A 95% A
Risk Return Profile  
Volatility (Standard Deviation) 127.17% 19% F 12% F
Risk Adjusted Return 106.03% 81% B- 95% A
Market Capitalization 1.71B 63% D 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 337.03 25% F 5% F
Price/Book Ratio 8.17 23% F 18% F
Price / Cash Flow Ratio 261.99 6% F 2% F
EV/EBITDA 1,138.99 4% F 1% F
Management Effectiveness  
Return on Equity -15.02% 38% F 38% F
Return on Invested Capital -0.05% 47% F 49% F
Return on Assets -1.47% 41% F 41% F
Debt to Equity Ratio 0.32% 94% A 91% A-
Technical Ratios  
Short Ratio 3.21 63% D 48% F
Short Percent 2.80% 59% F 56% F
Beta 1.44 28% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.